MedTrace Logo

The Effect of Lacosamide in Peripheral Neuropathic Pain

NCT03777956 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2023-02-16

No results posted yet for this study

Summary

The main purpose of this study is to compare the change in pain intensity during treatment with a sodium-channel blocker (lacosamide) in patients with peripheral neuropathic pain with and without the irritable nociceptor phenotype.

Conditions

  • Neuropathic Pain
  • Neuropathy;Peripheral
  • Neuropathy, Painful
  • Neuropathy, Diabetic
  • Neuropathy

Interventions

DRUG

Lacosamide

Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.

DRUG

Placebo

Identical placebo are given as capsules and taken orally twice a day.

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Danish Pain Research Center

    lead OTHER

Principal Investigators

  • Nanna B Finnerup, Professor · Danish Pain Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2022-06-03
Completion
2022-06-03

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03777956 on ClinicalTrials.gov